FUSION PHARMACEUTICALS INC (FUSN) Stock Price, Quote, News and Overview
NASDAQ:FUSN - Nasdaq - CA36118A1003 - Common Stock - Currency: USD
FUSN Quote, Performance and Key Statistics
21.55
+0.03 (+0.14%)
The current stock price of FUSN is 21.55 USD. In the past month the price increased by 0.47%. In the past year, price increased by 335.35%.
FUSN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FUSN
Company Profile
Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Hamilton Ontario, Ontario and currently employs 102 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing radiopharmaceuticals as precision medicines. The company has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.
Company Info
FUSION PHARMACEUTICALS INC
270 Longwood Rd. S
Hamilton Ontario ONTARIO L8P 0A6 CA
CEO: John Valliant
Employees: 102
Company Website: https://fusionpharma.com/
Phone: 12897990891
FUSION PHARMACEUTICALS INC / FUSN FAQ
What is the stock price of FUSION PHARMACEUTICALS INC today?
The current stock price of FUSN is 21.55 USD. The price increased by 0.14% in the last trading session.
What is the ticker symbol for FUSION PHARMACEUTICALS INC stock?
The exchange symbol of FUSION PHARMACEUTICALS INC is FUSN and it is listed on the Nasdaq exchange.
On which exchange is FUSN stock listed?
FUSN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FUSION PHARMACEUTICALS INC stock?
18 analysts have analysed FUSN and the average price target is 21.55 USD. This implies a price decrease of -0.01% is expected in the next year compared to the current price of 21.55. Check the FUSION PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FUSION PHARMACEUTICALS INC worth?
FUSION PHARMACEUTICALS INC (FUSN) has a market capitalization of 1.83B USD. This makes FUSN a Small Cap stock.
How many employees does FUSION PHARMACEUTICALS INC have?
FUSION PHARMACEUTICALS INC (FUSN) currently has 102 employees.
What are the support and resistance levels for FUSION PHARMACEUTICALS INC (FUSN) stock?
FUSION PHARMACEUTICALS INC (FUSN) has a support level at 21.49 and a resistance level at 21.56. Check the full technical report for a detailed analysis of FUSN support and resistance levels.
Is FUSION PHARMACEUTICALS INC (FUSN) expected to grow?
The Revenue of FUSION PHARMACEUTICALS INC (FUSN) is expected to decline by -82.55% in the next year. Check the estimates tab for more information on the FUSN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FUSION PHARMACEUTICALS INC (FUSN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FUSN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FUSN, evaluating the profitability, health, valuation and growth aspects
- FUSION PHARMACEUTICALS INC (FUSN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FUSION PHARMACEUTICALS INC (FUSN) Sales and EPS estimates to see what analysts future expectations are.
- FUSION PHARMACEUTICALS INC (FUSN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FUSION PHARMACEUTICALS INC (FUSN) Insider and Institutional Ownership to learn about the owners and their transactions.
- FUSION PHARMACEUTICALS INC (FUSN) Stock Chart to make your own analysis
- FUSION PHARMACEUTICALS INC (FUSN) Latest news and press-releases to stay up to date.
Does FUSION PHARMACEUTICALS INC (FUSN) stock pay dividends?
FUSN does not pay a dividend.
When does FUSION PHARMACEUTICALS INC (FUSN) report earnings?
FUSION PHARMACEUTICALS INC (FUSN) will report earnings on 2024-08-06, after the market close.
What is the Price/Earnings (PE) ratio of FUSION PHARMACEUTICALS INC (FUSN)?
FUSION PHARMACEUTICALS INC (FUSN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).
FUSN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to FUSN. When comparing the yearly performance of all stocks, FUSN is one of the better performing stocks in the market, outperforming 99.5% of all stocks.
FUSN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FUSN. The financial health of FUSN is average, but there are quite some concerns on its profitability.
FUSN Financial Highlights
Over the last trailing twelve months FUSN reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS increased by 28.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.2% | ||
| ROE | -43.12% | ||
| Debt/Equity | 0.21 |
FUSN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 70% to FUSN. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -0.46% and a revenue growth -82.55% for FUSN